Tag: Food and Drug Administration (FDA) ⋅ Page 3

Objective Intent: Professor Lietzan’s New Blog Focuses on Food and Drug Administration

Professor Erika Lietzan has launched a new blog, Objective Intent. In this blog, she and a co-author, Professor Patricia Zettler of Georgia State University, explore legal and policy issues associated with the U.S. Food and Drug Administration (FDA). Before joining the faculty of the University of Missouri, Professor Lietzan practiced FDA law for 18 years with one of the country’s…

Professor Lietzan Quoted on Selection of FDA Commissioner

Professor Erika Lietzan was recently quoted in BuzzFeed News regarding President Donald Trump’s selection of Dr. Scott Gottlieb to be the next commissioner of the U.S. Food & Drug Administration. Dr. Gottlieb was deputy commissioner under President George W. Bush and is currently a resident fellow at the American Enterprise Institute. Professor Lietzan noted that Dr. Gottlieb has a broad…

Citizen Petitions at the FDA: Professor Lietzan Interviewed by The Atlantic

Professor Erika Lietzan was recently interviewed by a reporter for The Atlantic in connection with the use of “citizen petitions” at the U.S. Food & Drug Administration (FDA). A recent article in the New England Journal of Medicine had pointed out that many petitions are filed by brand-name drug companies about products proposed by generic drug companies. Professor Lietzan commented…

Professor Lietzan Quoted on “Right to Try” Legislation

Professor Erika Lietzan was recently quoted in numerous papers around the country in connection with possible federal “right to try” legislation. Broadly speaking, the purpose of state “right to try” laws is to make it possible for terminally ill patients to receive unapproved drugs for treatment, if those drugs are currently in clinical trials and certain other conditions are met.…

Professor Lietzan Discusses Executive Order’s Possible Impact on Food and Drug Administration

Professor Erika Lietzan was quoted at length today in an article published by the Regulatory Affairs Professional Society (RAPS) about the impact of President Trump’s January 30 “two-for-one” executive order on the U.S. Food and Drug Administration (FDA). The executive order provides that whenever an agency promulgates a new regulation, it must identify at least two existing regulations to be…